Lumos Diagnostics Holdings Ltd. · ASX:LDX
Lumos Diagnostics — Shareholder Meeting (October 2021)
10 slides from Lumos Diagnostics's shareholder meeting presentation, Oct 28, 2021
Slide 1: Annual General Meeting
For personal use only Lumos Diagnostics Holdings Limited Annual General Meeting Rob Sambursky, MD CEO and President Lumos Diagnostics 28 October 2021 Confidential. This document and supporting materials contain confidential and proprietary business information from Lumos. www.lumosdiagnostics.com
Slide 2: Disclaimer and Important Information
Disclaimer and Important Information For personal use only This presentation (Presentation) has been prepared solely for informational purposes by Lumos Diagnostics Holdings Limited (Company). The information contained in this document (“Document”) has been prepared by Lumos Diagnostics Holdings Lim
Slide 3: FY21 At A Glance
FY21 At A Glance For personal use only A$25.0M total revenue in FY21 198% YoY increase “ While FY20 was all about integration and A$22.7M Commercial Services business unit revenue in FY21 188% YoY increase transformation, FY21 represented strategic action and growth. Global manufacturing capacity ex
Slide 4: Lumos Business Model
Lumos Business Model For personal use only Lumos is a fully integrated innovator, developer and manufacturer of rapid POC diagnostic solutions that allow clinicians and patients to make important medical decisions quickly and accurately. GLOBAL POC DIAGNOSTIC TEST SALES1 (US$ in billions) US$50B 50
Slide 5: FY21 Revenue
FY21 Revenue (A$ in thousands) For personal use only GROUP REVENUES (STATUTORY) GROUP REVENUES (HALF YEAR) REVENUE MIX BY BUSINESS SEGMENT COMMENTARY A record year Strong demand for services during FY21 • Lumos reporting group revenues of A$25.0M, up $198% on FY20 • High demand from partners for dev
Slide 6: FY21 Margin, OPEX & EBITDA
FY21 Margin, OPEX & EBITDA (A$ in thousands) For personal use only GROSS MARGIN (PRO FORMA)1 OPERATING EXPENSES (PRO FORMA) EBITDA (PRO FORMA) COMMENTARY Gross margin evolving with revenue mix Investment in growth and operations • Ahead of prospectus forecast • Actual EBITDA ahead of prospectus fore
Slide 7: FY22 First Quarter Highlights
FY22 First Quarter Highlights For personal use only LISTED ON THE ASX EXPANDED OPERATIONS Listed on the Australian Stock Commenced operations at its new Exchange (ASX) on 5 July 2021 manufacturing facility in Sarasota, following a successful Initial Florida, USA capable of producing Public Offering
Slide 8: FY22 Outlook
FY22 Outlook For personal use only “ Solid, diversifying revenue mix in FY22 driven by expansion of product business and contract manufacturing Lumos is well positioned as an emerging technology Broader engagement with clients as a result of expanded Commercial Services offerings leader in the rapid
Slide 9: FY22 Milestones & Achievements
FY22 Milestones & Achievements For personal use only • U.S. FDA 510(k) clearance: FebriDx® • DISRUPT clinical trial data in high impact • U.S. Emergency Use Authorization (EUA): peer reviewed publications ViraDx™ • FebriDx U.S. cost analysis in high impact • Health Canada Interim Order (IO): Regulat
Slide 10: For personal use only
For personal use only www.lumosdiagnostics.com
Lumos Diagnostics Holdings — Shareholder Meeting (October 2021) on 6ix